Project Grant R43CA309899
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $378K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $696,221 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop immunotherapy approaches for epithelial ovarian cancer by reprogramming virus-primed T cell immunity. The project evaluates engineered oncolytic Newcastle Disease Virus expressing IL-12 combined with bispecific T cell engagers to redirect antiviral T cell responses against ovarian cancer cells, myeloid cells, and...
- The National Cancer Institute awarded The Wistar Institute of Anatomy and Biology $473,624 on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate how myeloid cell-derived interleukin 1B promotes chemoresistance in metastatic ovarian cancer and to test whether combining interleukin 1B neutralization with chemotherapy overcomes chemoresistance. The research addresses why ovarian cancer patients initially responsive to front-line chemotherapy develop...
- The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $988,320 on September 11, 2025, under the Cancer Biology Research program (CFDA 93.396). The award funds research characterizing the involvement of FXR1 (Fragile X Mental Retardation Autosomal Related Protein-1), an RNA binding protein, in ovarian cancer progression. The research focuses on how FXR1 mRNA is encapsulated...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center $444,569 on September 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate cuproptosis—a copper-dependent form of regulated cell death—as a therapeutic pathway against chemoresistant high-grade serous ovarian cancer (HGSOC). The research addresses HGSOC's clinical challenge: most patients relapse after platinum-based chemotherapy, and recurrent disease develops resistance through adaptive,...
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...
- The National Cancer Institute awarded $400,000 to Intra Therapeutics, Inc. on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop IT-001, a localized cancer immunotherapy for intratumoral injection. IT-001 combines interleukin-12 (IL-12) with a proprietary injectable hydrogel designed to retain the cytokine within tumors for up to four weeks while minimizing systemic toxicity. Preclinical data demonstrate that a single IT-001 treatment produces complete...
- The National Institutes of Health National Cancer Institute awarded The Medical College of Wisconsin, Inc., $580,985 on June 25, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing Project Grant R01CA313995) to investigate the role of B cell subpopulations in ovarian cancer progression and immunotherapy response. The recipient will delineate the functions of distinct B cell subtypes and their interactions with immune cells in the high-grade serous ovarian cancer...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
- The National Cancer Institute awarded the University of Pittsburgh $638,422 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define the impact of detachment sensing proteins in ovarian cancer metastasis. The research identifies and characterizes genes and signaling pathways essential to peritoneal metastasis in high-grade serous ovarian adenocarcinoma, focusing on RHOV, an atypical GTPase that functions as a novel TGF-β/SMAD signaling integrator. The project uses in...